ERBB2 and breast carcinoma: To understand the molecular basis for resistance to HER2-targeted therapies, we previously established a trastuzumab-resistant breast cancer cell line (named as BT-474-R) from a trastuzumab-sensitive cell line with HER2 amplification (BT-474) by treating BT-474 cells with increasing doses of trastuzumab [23].